心肌缺血是因为冠状动脉疾病中心肌耗氧量和氧输送间的不协调引起的，由于其高发病率和死亡率，中国死于缺血性心脏病患者的数量逐年递增。为了验证金露梅有效成分具有抗心肌缺血功效，通过前期试验确定最大耐受浓度（maximum tolerance concentration, MTC）为15.63 μg/mL，并依据MTC划分高中低剂量组分别为7.81 μg/mL（1/2 MTC）、2.60 μg/mL（1/6 MTC）、0.868 μg/mL（1/18 MTC），阳性药物组为N-乙酰半胱氨酸（125 μg/mL）。借助网络药理学及分子对接技术的方法研究金露梅有效成分抑制心肌细胞凋亡，减缓心肌缺血的可能作用机制。结果表明：借助斑马鱼心脏荧光强度表型图发现金露梅水提物与阳性药物组对比具有明显的防治心肌缺血功效，而且其作用机制与Rap1信号通路、癌症通路、癌症中的蛋白巨糖、PI3K-Akt信号通路、脂质和动脉粥样硬化5条通路有关。可见探究金露梅有效成分的抗心肌缺血机制对防治心肌缺血有一定的理论意义。

Myocardial ischemia is caused by the incoordination between myocardial oxygen consumption and oxygen delivery in coronary artery disease, and due to its high morbidity and mortality rate, the number of patients who die from ischemic heart disease in China is increasing year by year. In order to verify that the active ingredients of Jinlume have anti-myocardial ischemic efficacy. The maximum tolerated concentration (MTC) was determined to be 15.63 μg/mL by the pre-test, and the high school and low dose groups were divided into 7.81 μg/mL (1/2 MTC), 2.60 μg/mL (1/6 MTC) based on the MTC, respectively, 0.868 μg/mL (1/18 MTC), and the positive drug group was N-acetylcysteine (125 μg/mL). With the help of network pharmacology and molecular docking technology, the possible mechanism of action of the active ingredients of Jinlume in inhibiting cardiomyocyte apoptosis and slowing down myocardial ischemia was investigated. The results showed that the aqueous extract of Jinlume had significant effects against myocardial ischemia in comparison with the positive drug group by means of zebrafish cardiac fluorescence intensity phenotyping, and its mechanism of action was related to five pathways, namely, Rap1 signaling pathway, cancer pathway, proteoglycans in cancer, PI3K-Akt signaling pathway, lipids, and atherosclerosis. It can be seen that exploring the anti-myocardial ischemic mechanism of the active ingredients of Jinlume has certain theoretical significance for the prevention and treatment of myocardial ischemia.